ADIPOQ and metabolic dysfunction-associated steatohepatitis: Previous studies have shown that TZD can increase the serum level of adiponectin, which is known to be associated with an increased risk of MetS and CVD.[41] Our results suggest the need for additional assessments of risk factors for T2DM, CVD, and MetS in clinical studies of TZD treatment for NAFLD or NASH.